Oregon Failure to Diagnose Cancer Lawyer

The Injury Is the Stage Shift

In a missed-cancer case the injury is rarely the cancer itself. It is the difference between the stage the disease would have been at had it been found when the record shows it should have been, and the stage it had reached by the time someone acted. That difference is what changes the medicine: whether an operation is still possible, whether chemotherapy is given to cure or to control, whether the surgery is smaller or larger, and whether the plan is measured in years or in months.

The National Cancer Institute's SEER program publishes five-year survival by stage at diagnosis, and the pattern is the same across nearly every cancer. Read the table below with four things in mind. These are relative survival figures — cancer patients compared with a matched general population — and they are population averages across everyone diagnosed from 2016 through 2022. They are not a prognosis for any individual patient. SEER's Localized / Regional / Distant categories are Summary Stage, which is not the same system as the AJCC TNM stages (I through IV) that appear in medical records; the two cannot be equated. And SEER caps the displayed value at 100.0%, which reflects survival at least as good as the comparison population — not that no one dies.

† SEER displays relative survival capped at 100.0%. It means survival in this group was at least as good as the matched general population over five years, not that the disease is never fatal. ‡ Bladder's all-stages figure sits above its localized figure because SEER reports a separate in situ category for bladder (98.0% five-year relative survival, covering half of all cases), which is folded into the all-stages number. The lung row is all lung and bronchus cancers, including small cell; SEER does not break out non-small cell lung cancer separately.

The distribution of stages at diagnosis is what makes the argument concrete. In the same SEER data, 51% of lung and bronchus cancers, 54% of ovarian cancers and 51% of pancreatic cancers are already distant when they are found, against 6% of female breast cancers and 5% of melanomas. Colorectal cancer sits in between: 34% localized, 37% regional, 23% distant. Cancers that are usually caught early are caught early because someone was looking — screening, a symptom taken seriously, a film read carefully. When that does not happen, a patient joins the distant column, and the survival difference between the columns is the measure of what was lost.

Stage shift is a genuine concept in cancer screening research, not a litigation invention. The same literature is candid about its limits: a shift toward earlier stage does not automatically produce a proportional reduction in deaths, and defense experts will raise lead-time bias, overdiagnosis, and stage migration — the effect by which better staging technology reclassifies patients and improves apparent survival in every stage without anyone living longer. Population tables describe a pattern. They do not, by themselves, establish what would have happened to one patient. That takes a treating or retained oncologist willing to say what the earlier stage would have meant for this person.

What Gets Missed, Cancer by Cancer

Each cancer has a characteristic signal that gets overlooked. The pattern is almost never a physician who considered cancer and rejected it; it is a finding that was documented and then treated as somebody else's job. The linked articles go through each one in detail.

If none of those fits, start with the two general articles: delayed cancer diagnosis in Oregon and could my doctor have diagnosed my cancer sooner?

Screening Guidelines and What They Actually Say

Screening guidelines are evidence a case is built with, not the legal standard itself. In Oregon the standard of care is the degree of care, skill and diligence used by ordinarily careful physicians in the same or a similar community under ORS 677.095, and it is proven with expert testimony. A guideline is a reference point an expert uses; it is not a substitute for one. Two national bodies matter most, and they do not always agree.

• Breast. The U.S. Preventive Services Task Force updated its statement on April 30, 2024: biennial screening mammography for women aged 40 to 74, a B recommendation. It calls the evidence insufficient (Grade I) for women 75 and older and for supplemental ultrasound or MRI in dense breasts. The American Cancer Society differs — annual mammography for ages 45 to 54, the option of annual screening from 40, annual or biennial from 55, and no fixed upper age limit so long as the patient is in good health with at least a ten-year life expectancy.
• Colorectal. USPSTF, 2021: screen adults 45 to 49 (Grade B) and 50 to 75 (Grade A), with selective screening from 76 to 85 (Grade C). Accepted strategies include colonoscopy every 10 years, annual FIT or high-sensitivity gFOBT, stool DNA-FIT every one to three years, CT colonography every five years, and flexible sigmoidoscopy every five years. The Task Force is explicit that abnormal stool-test results require follow-up colonoscopy for the benefit of screening to be realized. ACS also starts at 45 and additionally lists a blood-based test as an option, which the 2021 USPSTF statement does not.
• Lung. USPSTF, 2021, Grade B: annual low-dose CT for adults aged 50 to 80 with a 20 pack-year smoking history who currently smoke or quit within the past 15 years. ACS now agrees on the same criteria. The older 55-to-80, 30-pack-year threshold is the retired 2013 version and should not be applied to care delivered after 2021.
• Cervical. The USPSTF recommendation in force is still the one published August 21, 2018: cytology every three years for ages 21 to 29, and for ages 30 to 65 either cytology every three years, high-risk HPV testing alone every five years, or co-testing every five years. A draft update was posted in December 2024 and has not been finalized, so the 2018 statement governs. ACS differs: begin at 25, with primary HPV testing every five years as the preferred strategy.
• Prostate. USPSTF, 2018, still current: for men 55 to 69 the decision to undergo periodic PSA screening should be an individual one (Grade C); against screening at 70 and older (Grade D). Those grades govern whether to screen an asymptomatic man. They say nothing about what to do with a PSA that has already come back elevated. That question is governed by the American Urological Association's early-detection guideline (2023, amended 2026), which directs clinicians to repeat a newly elevated PSA before moving to a secondary biomarker, imaging or biopsy, and notes that the customary 4 ng/mL threshold is too high for men in their 40s and 50s. Doing nothing with a confirmed, repeated elevation is not a recognized pathway.

Failure to Follow Up: Its Own Theory of Liability

A large share of missed-cancer cases involve no diagnostic disagreement at all. The finding was made. The report was written. Nobody closed the loop. Three variants recur: an abnormal result that never reached the patient, a referral that was recommended and never placed, and imaging that was supposed to be repeated at an interval and never was.

This is measurable, and it has been measured. A 2009 study of 5,434 patient records across 23 physician practices found 135 apparent failures to inform patients of clinically significant abnormal results out of 1,889 such results — 7.1%, about one in fourteen — with individual practices ranging from 0% to 26.2%. Notably, having an electronic medical record did not by itself reduce the failure rate, and increased it where the practice lacked a real process for managing results. A companion study of 123,638 imaging studies found that 1,196 generated critical result alerts, and that 7.7% of those alerts lacked timely follow-up; among those, 28% eventually led to a new diagnosis, which was cancer in eleven cases. Risk of no timely follow-up was lower when the radiologist added verbal communication. (Both studies describe practice before the 2021 information blocking rules that now push most results directly to patient portals, and should be read with that in mind.)

Delay in following up is not automatically actionable, and the best colorectal evidence says so plainly. In Corley and colleagues' study of 70,124 patients with a positive fecal immunochemical test (JAMA 2017;317(16):1631–1641), colonoscopy at two, three and four to six months showed no significant difference in colorectal cancer risk compared with colonoscopy at 8 to 30 days. The signal appeared later: at 10 to 12 months, an odds ratio of 1.48 for colorectal cancer and 1.97 for advanced-stage disease; beyond 12 months, 2.25 and 3.22. That is the honest shape of the evidence, and it is more useful than a slogan. A two-month scheduling delay is not a case. A positive FIT that sat in a chart for a year is a very different matter.

Oregon Deadlines — and Why They Are Harder Here

Missed-cancer cases sit awkwardly with Oregon's filing deadlines, because the harm is discovered long after the act that caused it. Under ORS 12.110(4), a claim for injury arising from medical treatment or omission must be brought within two years from the date the injury is first discovered or, in the exercise of reasonable care, should have been discovered. But the same subsection imposes an absolute outer limit: five years from the date of the treatment, omission or operation, applicable notwithstanding ORS 12.160. That phrase matters. It means minority does not extend the five-year repose — a child whose cancer was missed does not get until age 19 or 20, and the common shorthand to that effect is wrong for medical malpractice. The only escape is the statute's narrow provision for cases where no action was filed within five years because of fraud, deceit or misleading representation, which then allows two years from discovery of that conduct.

If the patient died, the claim belongs to the personal representative of the estate under ORS 30.020, and the deadline is commonly misstated. The statute gives three years after the injury causing the death is discovered or reasonably should have been discovered, and then caps that at the earliest of three years after the death or the longest statute of ultimate repose applicable to the act — including the five-year repose in ORS 12.110(4). It is not “three years from the date of death.” A death that follows a misread scan by more than five years can be barred before the three years ever run.

If the provider was OHSU, a county hospital, a public health clinic or another public body, the Oregon Tort Claims Act controls, and the two branches are different lengths. Under ORS 30.275(2), notice of claim must be given within 180 days for an injury claim and within one year for wrongful death. The suit itself must be filed within two years under ORS 30.275(9) — shorter than the three-year wrongful death period, so a government wrongful death case is a one-year-notice, two-year-filing case, not a three-year case. Notice can be satisfied in more than one way, including actual notice or commencing the action within the notice period, but the plaintiff bears the burden of proving it. OHSU is subject to the state-level damage limits under ORS 30.271(5), not the lower limits that apply to cities and counties.

One more note on damages: Oregon's $500,000 cap on noneconomic damages in ORS 31.710 now applies only to wrongful death claims, which is exactly the posture many missed-cancer cases end up in. Before that matters, though, check the two categories the statute excepts on its face. The cap does not reach a claim against a public body, so a cancer death at OHSU or a county hospital is governed by the Tort Claims Act limits instead. And it does not reach a claim subject to workers’ compensation — an exclusion wider than it reads, which covers third-party claims brought by or for a worker injured in the course and scope of employment. That one earns its place on a cancer page: occupational disease claims, from asbestos and mesothelioma to benzene and occupational bladder cancer, are exactly the shape it fits, and it removes the cap by statute with no constitutional argument needed. For a death claim the cap does reach, Oregon appellate courts have declined to hold it categorically unconstitutional in wrongful death cases but have struck its application as-applied where it would leave a plaintiff without a substantial remedy. That analysis is fact-specific and covered in detail here.

Proving a Missed-Cancer Case in Oregon

ORS 677.095 states the duty: a physician licensed in Oregon must use the degree of care, skill and diligence used by ordinarily careful physicians in the same or similar circumstances in the physician's community or a similar community. It is a same-or-similar-community standard, not a national one, and by its terms the statute says nothing about how the standard is proven. The requirement of expert testimony is judicial, not statutory: Getchell v. Mansfield, 260 Or 174 (1971), and Trees v. Ordonez, 354 Or 197 (2013), hold that in most professional negligence cases expert testimony is required to establish the standard of care. A narrow common-knowledge exception exists for conduct a lay jury can judge without help — a retained sponge, an unsterilized instrument — and it almost never fits a diagnostic cancer case. Oregon has no certificate-of-merit statute, so nothing must be attached to the complaint; that is a filing rule, not a reason to file before the expert work is done.

Causation is where these cases are won and lost. Oncologists do not testify in percentages drawn from a website. They testify about stage at diagnosis, nodal status and metastatic burden; about resectability; and above all about treatment intent — whether the patient moved from curative to palliative, from lumpectomy to mastectomy, from surgery alone to surgery plus systemic therapy. There is published support for the harm of delay in starting treatment: a 2020 systematic review and meta-analysis in the BMJ covering 1,272,681 patients found that a four-week delay in surgery carried hazard ratios of roughly 1.06 to 1.08, and systemic therapy 1.01 to 1.28, with significant associations in 13 of 17 indications — and no significant association for adjuvant radiotherapy after breast-conserving surgery. That study measured delay in treatment, not delay in diagnosis, and should not be cited as if it quantified the latter.

The evidence itself is documentary. Huegli Law obtains the complete record from every treating facility, including the original imaging files rather than the reports alone — so an independent radiologist can look at the study that was called normal — plus pathology slides for re-review, referral and order histories, and the electronic health record audit trail. The audit trail is frequently decisive: a critical result flagged abnormal and never opened tells a different story than one that was opened, acknowledged, and then not acted on.